Home › Myelodysplastic Syndromes › Montana › Billings
Myelodysplastic Syndromes clinical trials in Billings, MT
3 studies for Myelodysplastic Syndromes are looking for participants at sites in and around Billings (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
- Billings Clinic Cancer Center, Billings
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Billings Clinic Cancer Center, Billings
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Billings
About Myelodysplastic Syndromes
Myelodysplastic Syndromes (MDS) are rare. They are sometimes found during a routine blood test. Learn symptoms, risk factors, and treatment options.
More about Myelodysplastic Syndromes on MedlinePlus
Myelodysplastic Syndromes trials in other cities
- Houston, TX43 studies
- Baldwin Park, CA26 studies
- New York City, NY21 studies
- Seattle, WA21 studies
- Washington, DC20 studies
- Tampa, FL19 studies
- Boston, MA19 studies
- Miami, FL17 studies
- Durham, NC14 studies
- Columbus, OH14 studies
- St. Louis, MO13 studies
- Atlanta, GA13 studies
Other studies in Billings
- Non-Small Cell Lung Cancer17 studies
- Prostate Cancer15 studies
- Lung Cancer13 studies
- Breast Cancer10 studies
- Ovarian Cancer9 studies
- Melanoma7 studies
- Chronic Lymphocytic Leukemia7 studies
- Acute Myeloid Leukemia7 studies
- Bladder Cancer6 studies
- Colon Cancer6 studies
- Colorectal Cancer6 studies
- Rectal Cancer5 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.